

*To Promote the Progress*

*of Science and Useful Arts*

## *The Director*

*of the United States Patent and Trademark Office has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.*

*Therefore, this United States*

# *Patent*

grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b). See the Maintenance Fee Notice on the inside of the cover.

*Katherine Kelly Vidal*

DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE



US011771730B2

(12) **United States Patent**  
**Goudet**

(10) **Patent No.:** **US 11,771,730 B2**  
(45) **Date of Patent:** **Oct. 3, 2023**

(54) **COMBINATION OF RHODIOLA AND  
ASTRAGALUS FOR THE TREATMENT OF  
NEURODEGENERATIVE DISEASES**

(71) Applicant: **HUMAN BY NATURE**, Toulouse (FR)

(72) Inventor: **Gérald Goudet**, Fiac (FR)

(73) Assignee: **HUMAN BY NATURE**, Toulouse (FR)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 48 days.

(21) Appl. No.: **16/969,410**

(22) PCT Filed: **Feb. 15, 2019**

(86) PCT No.: **PCT/FR2019/050342**

§ 371 (c)(1),

(2) Date: **Aug. 12, 2020**

(87) PCT Pub. No.: **WO2019/158870**

PCT Pub. Date: **Aug. 22, 2019**

(65) **Prior Publication Data**

US 2021/0052683 A1 Feb. 25, 2021

(30) **Foreign Application Priority Data**

Feb. 15, 2018 (FR) ..... 1851298

Feb. 16, 2018 (FR) ..... 1851319

(51) **Int. Cl.**

**A61K 36/41** (2006.01)

**A61K 31/7034** (2006.01)

**A61K 36/481** (2006.01)

**A61P 25/28** (2006.01)

**A61K 31/7028** (2006.01)

**A61K 31/7048** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 36/41** (2013.01); **A61K 31/7034**  
(2013.01); **A61K 36/481** (2013.01); **A61P**  
**25/28** (2018.01); **A61K 31/7028** (2013.01);  
**A61K 31/7048** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

#### U.S. PATENT DOCUMENTS

2008/0081046 A1 \* 4/2008 Olalde ..... A61K 36/07

424/769

2008/0118583 A1 \* 5/2008 Olalde Rangel ..... A61K 36/00

424/728

2009/0110674 A1 \* 4/2009 Loizou ..... A61K 36/00

424/94.2

#### FOREIGN PATENT DOCUMENTS

CN 1981857 A \* 6/2007

CN 1981857 A 6/2007

CN 102940787 A 2/2013

KR 20030007105 A 1/2003

#### OTHER PUBLICATIONS

Huang (CN 1981857A, Aug. 12, 2020 IDS, machine translation of  
Description.\*

Morgan, M., Bone, K., Rhodiola rosea—Rhodiola, Medi Herb—a  
phytotherapist's perspective, No. 47 Feb. 2005.\*

"Héritez de la nature toute sa jeunesse . . ." or "Inherit from Nature  
all its Youth . . .", Composition d'ADN Téloméreactives ©, (2017)  
<http://www.adn-astragale.fr/astragale>.

International Search Report received in PCT/FR2019/050342, dated  
May 16, 2019.

Nabavi et al., "Rhodiola rosea L. and Alzheimer's Disease: From  
Farm to Pharmacy", Phytotherapy Research, (2016), vol. 30, pp.  
532-539.

Xia et al., "Neuroprotective Effects of Astragaloside IV on Parkinson  
Disease Models of Mice and Primary Astrocytes", Experimental  
and Therapeutic Medicine, (2017), vol. 14, pp. 5569-5575.

"Héritez de la nature toute sa jeunesse . . ." Composition d'ADN  
Téloméreactives ©, (2017) <http://www.adn-astragale.fr/astragale>.

Haiyan et al., "Effect of Astragaloside IV on Neural Stem Cell  
Transplantation in Alzheimer's Disease Rat Models." Evidence-  
Based Complementary and Alternative Medicine. 2016. 8 pages.

\* cited by examiner

Primary Examiner — H. Sarah Park

(74) Attorney, Agent, or Firm — ARENTFOX SCHIFF  
LLP

(57) **ABSTRACT**

The present invention relates to a product containing an  
extract of *Rhodiola* and an extract of *Astragalus* as products  
to be combined for simultaneous administration, separately  
or staggered over time, in the treatment of a neurodegener-  
ative disease, and in particular for the treatment of  
Alzheimer's disease and Parkinson's disease.

**12 Claims, 8 Drawing Sheets**